To provide long-term growth through investment mainly in UK equities. These tend to be leading UK companies and may have significant overseas earnings. Smaller companies may also be included.
Name | % Net Assets |
---|---|
HSBC | 7.2% |
BG Group | 5.4% |
GlaxoSmithKline | 4.7% |
Centrica | 4.1% |
HSBC | 3.8% |
BG Grp | 3.4% |
Imperial Tobacco | 3.3% |
Cable & Wireless | 2.8% |
Xtrata | 2.8% |
Shire | 2.5% |
Key | % Net Assets |
---|---|
HSBC | 7.2% |
BG Group | 5.4% |
GlaxoSmithKline | 4.7% |
Centrica | 4.1% |
Other | 78.6% |
Date | 27-Jan-2023 |
---|---|
NAV | 3,446.00p |
Currency | GBP |
Change | 2.00p |
% | 0.06% |
YTD change | 3,446.00p |
YTD % | n/a |
Fund Inception | 24/04/1970 |
---|---|
Fund Manager | Roger Jones |
TER | 1.75 (30-Apr-2011) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | £1,000 |
Savings | £50 |
Charges | |
---|---|
Initial | 5.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.06 |
You are here: research